Researchers developed and validated a new lung cancer prediction model, Sybil-Epi, by integrating clinical and epidemiologic data with a pre-existing model.

As lung cancer screening identifies an estimated 1.6 million suspicious lung nodules each year in the U.S. alone, physicians ...

Two FDA-cleared technologies are now available to speed the detection of suspicious lung nodules and reduce the physical ...

Key Takeaways Catching tumors early is crucial to lung cancer survivalNew robotic technologies, along with other innovations, ...

UCLA scientists have developed a simple and cost-effective blood test that, in early studies, shows promise in detecting ...

Scientists have developed a simple and cost-effective blood test that shows promise for detecting multiple cancers, various ...

MethylScan is a low-cost blood test that detects cancers and organ diseases by analyzing DNA methylation, improving early diagnosis, and identifying disease origin.

MethylScan is a low-cost blood test that detects multiple cancers and liver diseases by analyzing DNA methylation patterns ...

Researchers suggest their approach has the potential to transform early disease detection and health monitoring across diverse clinical settings.

On April 9, 2026, Oxford BioTherapeutics announced a multi-year collaboration with Bristol Myers Squibb focused on the discovery and development of T-cell engager therapies for solid tumors. 1 ...